Hexa Reports Market Research Reports and Insightful Company Profiles
Antihypertensive Therapeutics in Major Developed Market Size, Share, Growth, Treatment, Analysis, Symptoms, Emerging Trends and Opportunities to 2021
Hypertension is a heart-related disease which results in elevated blood pressure in the arteries. It is also known as arterial hypertension or high blood pressure. This disease occurs on account of alcohol, smoking, obesity, and other genetic factors. Although, the disease can be treated with a healthy diet and exercise, antihypertensives are recommended to control it. Antihypertensives are a class of drugs which can prevent hypertension and other cardiovascular-related disorders like strokes and myocardial infarction. They are likely to reduce the heart conditions by 21%. Beta blockers, thiazide diuretics, ACE inhibitors, calcium channel blockers, and angiotensin II receptor antagonists (ARBs) are the different types of antihypertensive therapeutics in major developed markets. Browse Detail Report With TOC @ http://www.hexareports.com/report/antihypertensivetherapeutics-in-major-developed-markets/details Thiazide diuretics aid in reducing salt and water from the kidneys. They are the first drugs to be administered for a patient undergoing hypertension treatment. ACE inhibitors reduce serum creatinine levels better than beta blockers. They are considered the first line of defense against heart-related disorders. ARBs reduces the risko f myocardial infarction when combined with amlodipine. Beta blockers
Hexa Reports Market Research Reports and Insightful Company Profiles are considered risky and can lead to strokes or type-2 diabetes. However, they prevent heart attacks in persons who have already experienced a heart attack. The hypertension market was estimated to have earned USD 40 billion of revenue in 2013. The market will attain USD 37 billion by 2020, owing to the patent expiry of major drugs. It is predicted to grow at a 2.6% CAGR during the period of 2014 to 2017. The market will experience growth on account of fixeddose combination (FDCs) drugs, the rising geriatric population, and a low diagnosis rate. FDCs include Amturnide, Azor, Twynsta, Exforge Tribenzor, Valturna, Benicar HCT, Tekturna HCT, Tekamlo, and Edarbyclor. New drugs in the pipeline are AHU377 + valsartan and azilsartan + amlodipine. Patients undergoing the treatment were known to have reduced levels of blood pressure. Drugs about to lose their patent are Exforge in 2014, Cozaar in 2010, Tekturna and Tekturna HCT in 2018, Benicar in 2016, and Atacand and Avapro in 2012. Request A Sample copy of This Report @ http://www.hexareports.com/sample/104209 The hypertension market has evolved from creating drugs to providing step-by-step special treatment dependent on the seriousness of the disease. The new classes of antihypertensive drugs are able to protect the kidneys, liver, heart, and brain from internal damage. Table Of Content 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Pathophysiology 2.2 Etiology 2.3 Signs and Symptoms 2.4 Co-Morbidities and Complications 2.5 Diagnosis 2.6 Classification 2.7 Epidemiology 2.8 Prognosis 2.9 Treatment and Management 3 Marketed Products 3.1 Approved Products 3.2 Comparative Efficacy and Safety 4 Product Pipeline 4.1 Overall Pipeline
Hexa Reports Market Research Reports and Insightful Company Profiles 4.2 Pipeline Analysis by Molecules Type 4.3 Pipeline Analysis by Mechanism of Action Type 4.4 Clinical Trial Failure Rate 4.5 Patient Enrollment and Clinical Trial Size 4.6 Clinical Trial Duration 4.7 Promising Drug Candidates in Pipeline Browse All Pharmaceuticals & Healthcare Market Research Related Reports @ http://www.hexareports.com/category/pharmaceuticals-and-healthcare-market 5 Market Forecast 5.1 Introduction 5.2 Global Market 5.3 North America 5.4 Top Five European Countries 5.5 Japan 5.6 Drivers and Barriers 6 Deals and Strategic Consolidations 6.1 Licensing Deals 6.2 Co-development Deals 7 Appendix 7.1 Market Forecasts to 2020 7.2 All Pipeline Drugs by Phase 7.3 Abbreviations 7.4 References 7.5 Methodology 7.6 Expert Panel Validation 7.7 Contact Us 7.8 Disclaimer Browse Full Report @ http://www.hexareports.com/report/antihypertensive-therapeutics-in-majordeveloped-markets/details About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Hexa Reports Market Research Reports and Insightful Company Profiles Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/ Visit our Blog: http://hexareports.blogspot.com/